NCT06239415View on ClinicalTrials.gov

PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicylic Acid Combination Therapy (PRO-PAS)

RecruitingOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Peripheral Atherosclerotic Disease
Interventions
OTHER

observation

Observation for 1 year of patients suffering from symptomatic peripheral atherosclerotic disease of the lower limb, with or without chronic ischemic heart disease, and indication for treatment with rivaroxaban 2.5 mg bid and acetylsalicylic acid 100 mg.

Trial Locations (1)

Unknown

RECRUITING

Istituti Clinici Scientifici Maugeri, Milan

All Listed Sponsors
collaborator

Società Italiana Cardiologia Ospedalità Accreditata (SICOA)

UNKNOWN

lead

Istituti Clinici Scientifici Maugeri SpA

OTHER